Discover
OTLK
Outlook Therapeutics, Inc.
1.47
37 x 1.43
2 x 1.81
bid
ask
-
0.12
7.55%
20 @ 06:34 AM
1.47 +0.00 (0.00%)
| Ytd | -6.96% | |
| 1y | -6.96% |
1.42
day range
1.57
0.16
52 week range
3.39
| Open | 1.55 | Prev Close | 1.59 | Low | 1.42 | High | 1.57 | Mkt Cap | 177.67M |
| Vol | 8.77M | Avg Vol | 18.92M | EPS | -1.13 | P/E | N/A | Forward P/E | -0.55 |
| Beta | 0.63 | Short Ratio | 1.26 | Inst. Own | 35.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.73 | 200-d Avg | 0.90 | 1yr Est | 24.80 |
OTLK News
benzinga.com
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
Outlook Therapeutics Says FDA Accepts Resubmitted BLA For ONS-5010/LYTENAVA For Treatment Of Neovasc
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the stand
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
benzinga.com
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat N
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and